MRC1 and colorectal carcinoma: The trial reported an objective response rate (ORR) and progression-free survival (PFS) of 40% and 78%, respectively, for patients with MMR-deficient CRC, as compared with 0% and 11% seen in patients with MMR-proficient CRC [26].